European Journal of Surgical Oncology
Volume 35, Issue 4 , Pages 352-355 , April 2009

Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only

  • R.R. de Vries

      Affiliations

    • Department of Urology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • ,
  • J.A. Nieuwenhuijzen

      Affiliations

    • Department of Urology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • ,
  • W. Meinhardt

      Affiliations

    • Department of Urology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • ,
  • E.M. Bais

      Affiliations

    • Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    • ,
  • S. Horenblas

      Affiliations

    • Department of Urology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 20 5122559; fax: +31 20 5122554.

,Accepted 3 July 2008.

References 

  1. Wittekind Ch, Greene FL, Henson DE, Hutter RVP, Sobin LH. TNM classification of malignant tumours. Wiley-Liss; 2002;
  2. Nieuwenhuijzen JA, Bex A, Meinhardt W, et al. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol. 2005;174(1):80–85
  3. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006;42(8):1031–1039
  4. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–675
  5. Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol. 2001;165(3):811–814
  6. Dodd PM, McCaffrey JA, Herr H, et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol. 1999;17(8):2546–2552
  7. Sweeney P, Millikan R, Donat M, et al. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?. J Urol. 2003;169(6):2113–2117
  8. der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–4608
  9. Hall RR, Prout GR. Staging of bladder cancer: is the tumor, node, metastasis system adequate?. Semin Oncol. 1990;17(5):517–523

PII: S0748-7983(08)01701-0

doi: 10.1016/j.ejso.2008.07.001

European Journal of Surgical Oncology
Volume 35, Issue 4 , Pages 352-355 , April 2009

Article Tools

* Image Usage & Resolution